Trial intelligence / Profile preview

Tadalafil Once-Daily for BPH in Asian Men

NCT00861757Phase 3Completed

Sponsor
Eli Lilly and Company
Start
Mar 2009
Primary completion
Jun 2010
Modality
Small Molecules
Countries
2
01

Overview

Phase 3, randomised, double-blind trial of tadalafil in benign prostatic hyperplasia (BPH), sponsored by Eli Lilly and Company. Primary endpoint: International Prostate Symptom Score at 12 weeks. Started Mar 2009; status: completed.

02

Drugs

tadalafil
03

Conditions

benign prostatic hyperplasia (BPH)

Beyond the preview

Go deeper on NCT00861757.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00861757.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call